

2020 HFSA Annual Scientific Meeting : Non-CE
Course Details and Faculty Listing

COVID-19: Lessons Learned in Heart Failure and Living with the New Normal	
Presentation	Speaker(s)
Moderator (Introductions)	P. Liu; University of Ottawa Heart Institute, Ottawa, ON, CANADA.
Acute COVID-19 Cardiovascular Syndrome	N. Hendren; Internal Medicine, University of Texas-Southwestern, Dallas, TX.
RAAS Inhibitor Therapies and Other Core HF Therapies in Heart Failure (during the pandemic and when COVID-19 Positive)	P. Liu; University of Ottawa Heart Institute, Ottawa, ON, CANADA.
Social Distancing, Social Isolation and Heart Failure: Lessons Learned in Regard to Self-Care	B. Davidson; Association of American Heart Failure Nurses, Nashville, TN.
Telemedicine in COVID-19- Strengths, Limitations and Innovations Needed	M. Vaduganathan; Brigham and Women's Hospital Heart and Vascular Ce, Boston, MA.
Moderator (Panel Q&A)	N. M. Albert; Nursing Institute-Research and Innovation, Cleveland Clinic, Cleveland, OH.
Panel Discussion	
To Right A Wrong in Heart Failure	
Presentation	Speaker(s)
Moderator (Introductions)	M. Saltzberg; Medical College of Wisconsin, Milwaukee, WI.
Pathophysiology and Differential Diagnosis of Right Ventricular Dysfunction	M. Jacob; Cleveland Clinic, Cleveland, OH.
Assessment of Right Ventricular Function	R. J. Tedford; Medical University of South Carolina, Charleston, SC.
Medical Optimization of Right Ventricular in HFpEF and HFrEF	P. Shah; Inova Heart and Vascular Institute, Falls Church, VA.
Device Management in Right Ventricular Failure	N. K. Kapur; Tufts Medical Center, Boston, MA.
Moderator (Panel / Q&A)	M. Crespo-Leiro; University Hospital A Coruna, A Coruna Galicia, SPAIN.
Case Study & Panel Discussion	
Clinical Conundrums - Multidisciplinary Case Discussion	
Presentation	Speaker(s)
Moderator	J. Howlett; University of Calgary, Calgary, AB, CANADA.
Moderator	J. Wilcox; Northwestern University Feinberg School of Medicine, Chicago, IL.
Clinical Conundrums (Multidisciplinary Case Discussion)	P. Mather; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Clinical Conundrums (Multidisciplinary Case Discussion)	B. Davidson; American Association of Heart Failure Nurses, Nashville, TN.
Clinical Conundrums (Multidisciplinary Case Discussion)	R. J. D. DiDomenico; University of Illinois at Chicago, Chicago, IL.
Clinical Conundrums (Multidisciplinary Case Discussion)	S. Keteyian; Henry Ford Health System, Detroit, MI.
Beyond Socioeconomic & Access to Care: The Clinical Imperative for Understanding Racial HF Differences and Disparities	
Presentation	Speaker(s)
Moderator (Introductions)	A. A. Morris; Cardiology, Emory University, Atlanta, GA.
Racial Differences In Rates of Heart Failure Hospitalization and Death: A Growing Problem	B. Ziaean; David Geffen School of Medicine at UCLA, Los Angeles, CA.
Not Just a Man's Disease: The Disproportionate Burden of Heart Failure in Women of Color	E. Hsieh; Cleveland Clinic, Cleveland, OH.
Genetic Determinants that Contribute to the Higher Incidence of Heart Failure in Persons of African Ancestry	D. M. McNamara, Sr.; University of Pittsburgh Medical Center, Pittsburgh, PA.
A-HeFT or A-LEFT Behind? Disparities in the Medical Management of HFrEF in Black Patients	E. Lewis; Stanford University Medical Center, Stanford, CA.
Moderator (Panel / Q&A)	C. Yancy; Northwestern University Feinberg School of Medicine, Chicago, IL.
Panelist	K. Breathett; University of Arizona, Tucson, AZ.
Panelist	C. J. Rodriguez; Albert Einstein College of Medicine, Bronx, NY.
Case Study & Panel Discussion	
Heart Meets Kidney	
Presentation	Speaker(s)
Moderator (Introductions)	M. A. Brisco-Bacik; Temple Health & Vascular Institute, Philadelphia, PA.
Latest Insights to Pathophysiology of CRS	H. H. Chen; Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Diuretic Decongestion Strategies: Which DOSE, Route and Combination?	A. Bagnola; Inova Heart and Vascular Institute, Falls Church, VA.
Cardio-Renal Learnings From New Trials	J. P. Dwyer; Vanderbilt University Medical Center, Nashville, TN.
Non-Medication Based Therapeutic Strategies	J. M. Testani; Yale University, New Haven, CT.
Moderator (Panel / Q&A)	P. McCullough; Baylor Heart & Vascular Hospital, Dallas, TX.
Case Study & Panel Discussion	
Future HF Trials	
Presentation	Speaker(s)
Moderator	M. Konstam; Tufts Medical Center, Boston, MA.
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure	J. R. Teerlink; Cardiology, 111C, San Francisco VAMC/UCSF, San Francisco, CA.
AHF Studies with SGLT2 Inhibitors	Z. Cox; Vanderbilt University Medical Center, Nashville, TN.
Post-MI studies with SGLT2 inhibitors	J. A. Udell; Cardiology/Medicine, Women's College Hospital, Toronto, ON, CANADA.
IV Iron Replacement Outcomes Trials	R. J. Mentz; Medicine, Cardiology, Duke University Medical Center, Durham, NC.
PARADISE-MI	E. Lewis; Stanford University Medical Center, Stanford, CA.
Excellence in Translational Science: Fast Track Discovery to Application	
Presentation	Speaker(s)
Preamble and Objectives	P. Liu; University of Ottawa Heart Institute, Ottawa Canada, ON.
Technologies to Fast Track Translation - Single Cell Omics for Personalized Medicine	M. Snyder; Stanford University School of Medicine, Palo Alto, CA.
Technologies to Fast Track Translation - Big Data/AI Deep Modeling of Molecular Interactions	F. Lightstone; Lawrence Livermore/AHA Collaborative Initiative, Livermore, CA.
Technologies to Fast Track Translation - Power and Pitfalls of AI Applied to ECHO	C. Lam; National Heart Centre, Singapore/Duke-NUS Medical School, Singapore, SINGAPORE.
"Tom Force" Keynote Lecture: Myosin Myopathies: Pathogenesis and Potential Therapeutics	L. Leinwand; Howard Hughes Medical Institute, Boulder, CO.
Panel Discussion	Panel Moderators: Walter Koch, Joseph Wu, Discussants: Michael Snyder, Felice Lightstone, Carolyn Lam, Leslie Leinwand, Wilson Tang, Howard Rockman
Progress from Bench to Bedside and Insights Learned - Myosin Inhibitors (Mayacamten in HCM)	M. Semigran; MyoKardia, Brisbane, CA.
Progress from Bench to Bedside and Insights Learned - Myosin Activators	F. I. Malik; Cytokinetics, San Francisco, CA.
Progress from Bench to Bedside and Insights Learned - SPECIAL LECTURE: Limitations of Infarct Size - the Open Artery Hypothesis	E. Braunwald; Harvard Medical School, Brigham and Women's Hospital, Boston, MA.
Bedside to Bench Reverse Translation - SGLT2i in HF and Role of Autophagy	M. Packer; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX.
Bedside to Bench Reverse Translation - What COVID-19 has Taught Us About Translation	D. Mann; Washington University School of Medicine, St. Louis, MO.
Facilitating Translational Acceleration - NIH/NCATS Small Business Program	L. Portilla; National Institutes of Health, Bethesda, MD.
Facilitating Translational Acceleration - AHA	I. Benjamin; American Heart Association/Froedtert & Medical College of Wisconsin, Dallas, TX.
Facilitating Translational Acceleration - JMP	G. Singh; JMP Securities, San Francisco, CA.
Facilitating Translational Acceleration - FDA - Device -21	B. Zuckerman; Food and Drug Administration, Bethesda, MD.
Panel Moderators: Mariell Jessup, Joseph Hill, Discussants: Douglas Mann, Lili Portilla, Ivor Benjamin, Eric Rose, Gobind Singh, Bram Zuckerman	
Update on Medical Treatment Strategies in HF	

Presentation	Speaker(s)
How to Sequence New Therapies in HF	G. Fonarow; University of California Los Angeles, Los Angeles, CA.
Benefits of Comprehensive Medical Treatment	M. Vaduganathan; Brigham and Women's Hospital Heart and Vascular Center, Boston, MA.
How to Individualize Medical Treatment - One Size Does not Fit All	M. Nassif; Saint Lukes Mid America Heart Institute, Kansas City, MO.
Supporting the HF Workforce: Optimizing Physical and Mental Wellness Among HF Providers	
Presentation	Speaker(s)
Moderator (Introductions)	A. Moore Gibbs; Atrium Health - Sanger Heart & Vascular Institute, Charlotte, NC.
Clinician Well-Being A Healthy Policy Perspective	T. Shanafelt; Stanford Medicine - WellMD Center, Stanford, CA.
How to Identify and Act on Early Signs of Clinician Burnout	C. Sinsky; Sinsky Healthcare Innovations, Philadelphia, PA.
Tips for Healthy Living at Work: Staying Active and Eating Healthy	R. Arena; University of Illinois at Chicago, College of Applied Health Sciences, Chicago, IL.
Burnout and Quality of Work Life Among Cardiology Practitioners	J. Casida; Johns Hopkins University, Baltimore, MD.
Role of Professional Societies in Support and Protecting HF Clinicians Against Burnout (Physician)	P. Harris; American Medical Association, Washington, DC.
Role of Professional Societies in Support and Protecting HF Clinicians Against Burnout (Nurse)	C. Lewis; Vanderbilt University Medical Center, Nashville, TN.
HF and the End of Life - Opportunities for Innovation and Collaboration at the Intersection of Cardiology and Palliative Care	
Presentation	Speaker(s)
Moderator (Introductions)	A. O'Donnell; Department of Cardiology, Boston University School of Social Work, Boston, MA.
Role of Early Palliative Care for Heart Failure: Planning Ahead without Creating Much Ado about Nothing	S. Chuzi; Northwestern University, Chicago, IL.
Advanced Therapies and Palliative Care: Big Decisions, Big Considerations, Big Feelings	H. Warraich; Brigham and Women's Hospital/Boston Veterans Affairs Medical Center, Boston, MA.
Innovative Partnerships Between Palliative Care and Heart Failure Cardiology: Creating a Team of Teams	K. R. Dobbie; Palliative Medicine, Cleveland Clinic, Cleveland, OH.
Social Determinants and Financial Considerations at End of Life: In Hospice You Can Keep Doing Everything That Makes You Feel Better ... Except For This Long List of Things	A. V. Ambardekar; University of Colorado, Aurora, CO.
Caregiver Burden in Advanced Heart Failure: The Forgotten	R. M. Masterson Creber; Healthcare Policy & Research, Weill Cornell Medicine, New York City, NY.
Moderator (Panel / Q&A)	A. S. Laramie; University of Vermont Medical Center, Burlington, VT.
Case Study & Panel Discussion	
2020 and Beyond: Background Medical Therapy for Clinical Trials	
Presentation	Speaker(s)
Moderator (Introductions)	O. Vardeny; Minneapolis VA Health Care System, Minneapolis, MN.
Basic Necessities	G. Fonarow; University of California, Los Angeles, CA.
New Drugs - Dapagliflozin, Vericiguat, Empagliflozin	C. O'Connor; Inova, Falls Church, VA.
GDMT Score	M. Fiuzat; Durham, NC.
HFpEF - Should There Be A Standard?	S. Solomon; Brigham and Women's Hospital, Boston, MA.
Moderator (Panel / Q&A)	J. R. Teerlink; San Francisco VAMC/UCSF, San Francisco, CA.
Panelist	A. Hernandez; Duke University, Durham, NC.
Panelist	N. Stockbridge; Food and Drug Administration, Bethesda, MD.
Panelist	
Panelist	B. Zuckerman; Food and Drug Administration, Bethesda, MD.
Contemporary Challenges in Heart Transplantation: A New Decade, New Opportunities	
Presentation	Speaker(s)
Moderator (Introductions)	K. Schlendorf; Vanderbilt University Medical Center, Nashville, TN.
Time for a Tune-up: Let the Pharmacist under the Hood Before You Hit the Road	D. Jennings; Columbia University Medical Center, New York, NY.
Charting the Course: Navigating through the New Allocation System to a Successful Transplant	R. J. Cogswell; Medicine, University of Minnesota, Minneapolis, MN.
Finding the Right Travel Buddy: When Should the Kidney Come Along for the Ride?	B. Trachtenberg; Houston Methodist, Houston, TX.
Check the Tire Pressure! What do to When Your Patient has Pre-transplant Pulmonary Hypertension	A. Guha; Cardiology, Houston Methodist, Houston, TX.
Pumping the Breaks on Bad Antibodies: Contemporary Approaches to Sensitized Heart Transplant Candidates	M. Habal; Columbia University, New York, NY.
Moderator (Panel / Q&A)	L. Peters; Advanced Heart Failure and Cardiac Transplantation, University of Colorado, Boulder, CO.
Case Study & Panel Discussion	
HF Hospitalizations and Transitions of Care: It Takes A Village	
Presentation	Speaker(s)
Moderator (Introductions)	G. Jackson; Cardiology, Medical University of South Carolina, Charleston, SC.
Inpatient Pathways and Team-Based Care to Improve Post-Discharge Outcomes of Hospitalized Heart Failure Patients	S. Hollenberg; Hackensack Meridan University, Hackensack, NJ.
Smoothing Heart Failure Care Transitions: Contemporary Strategies Utilizing Case Managers and APNs	N. M. Albert; Cleveland Clinic, Cleveland, OH.
Get the Medications Right: Pharmacists Optimizing GDMT During Transitions of Care	V. Groo; University of Illinois at Chicago, Chicago, IL.
Whose Job is it Anyway? Managing Comorbidities Following Heart Failure Discharge	S. M. Joseph; Baylor University Medical Center, Dallas, TX.
The "Other" Transition: When and How to Consider Palliative Care in Patients with Heart Failure	J. Rogers; Duke University Health System, Durham, NC.
Moderator (Panel/ Q&A)	P. Kirkwood; St. Joseph Heritage Healthcare, CA.
Case Study & Panel Discussion	
JNC New Investigator Award: Basic, Translational and Clinical	
Presentation	Speaker(s)
Moderator (Introductions)	R. C. Starling; Cleveland Clinic, Cleveland, OH.
Validation Of Natriuretic Response Prediction Equation In Patients With Acute Decompensated Heart Failure	Olyvia Gleason; Yale University School of Medicine, New Haven, CT
Circulating Protein Biomarkers Associated With Heart Failure With Preserved Ejection Fraction	Jessica Regan; Duke University, Durham, NC
The Effect Of The Cardiac Myosin Activator, Omecamtiv Mecarbil, On Right Ventricular Structure	Tor Biering-Sørensen; Herlev and Gentofte Hospital, København Ø, Denmark
Race And Sex-specific Population Attributable Fractions For Incident Heart Failure: Lifetime Risk Pooling Project	Arjun Sinha; Northwestern Feinberg School of Medicine; Chicago, IL
A Novel Metabolomics Risk Score Associated With Sex-differences In Heart Failure	Aditi Nayak; Emory University, Atlanta, GA
Reviewer/Judge (Chair)	Jeffrey M. Testani, Yale University, New Haven, CT
Reviewer/Judge	Sheryl L. Chow, Western University of Health Sciences, Pomona, CA
Reviewer/Judge	John Burnett, Mayo Clinic, Rochester, MN
Reviewer/Judge	Muthiah Vaduganathan, Brigham and Women's Hospital Heart and Vascular Ce, Boston, MA
Reviewer/Judge	Jane Wilcox, Northwestern University Feinberg School of Medicine, Chicago, IL
Nurse Investigator Award: Research and Clinical	
Presentation	Speaker(s)
Moderator	J. Howie-Esquivel; Charlottesville, VA.

Moderator	M. Callihan; Allegheny Health Network, Pittsburgh, PA.
Enhancing Shared Decision Making In A Chronic Population. Use Of An Advance Directive Decision Aid For Patients With Heart Failure And Their Caregivers.	Emily Benton; University of Colorado Denver, CO
Predictive Model For Risk Of 30-day Rehospitalization Using A Natural Language Processing/machine Learning Approach Among Medicare Patients With Heart Failure	Youjeong Kang; University of Utah, Salt Lake City, UT
Blacks With Hypertrophic Cardiomyopathy Have Lower Quality Of Life And Exercise Capacity Than Whites	Milla Arabadjian; NYU Rory Meyers College of Nursing; New York, NY
Virtual Outpatient Heart Failure Care - Lessons From The Covid-19 Era	Sharon Ugolini; University of Utah Heath Salt Lake City, UT
Reducing Heart Failure Readmissions Through A Shared Medical Appointment	Lisa Filyo; VA, Orlando, FL
Our Experience With Using Watchpat® (itamar Medical, Ltd.), Home Sleep Testing (hst) For The Diagnosis Of Sleep Apnea In Advanced Heart Failure Patients	Sandra Carey; Baylor Scott and White HCS, Colleyville, TX
Reviewer/Judge	W. Alonso; College of Nursing, University of Nebraska Medical Cent, Omaha, NE.
Reveiwier/Judge	Q. E. Denfeld; School of Nursing, Oregon Health & Science University, Portland, OR.
Reviewer/Judge	C. Lewis; Vanderbilt University Medical Center, Nashville, TN.
Reviewer/Judge	J. Bidwell; University of California, Davis, Davis, CA.
Reviewer/Judge	P. E. Brennan; Transplant, Tampa General Hospital, Tampa, FL.
Friday Plenary : Impact of Music in HF - A Live Panel Discussion	
Presentation	Speaker(s)
Introductions of Moderators and Panel	B. Bozkurt; Dallas, TX.
Moderator	M. Rich; Washington University, St. Louis, St. Louis, ME.
Beneficial Effects of Listening to Classical Music in Patients with HF: a Randomized Controlled Trial	P. Hauptman; University of Tennessee Knoxville, Knoxville, TN.
Panel	R. Fleming; Soprano Renée Fleming, -, DC.
Panel	E. Edwards; National Center for Complementary & Integrative Health, Bethesda, MD.
Panel	J. Fleg; National Center for Complementary & Integrative Health, Bethesda, MD.
Panel	J. Kulinski; Medical College of Wisconsin, HUB for Collaborative Medicine, Wauwatosa, WI.
Panel	S. Robb; Indiana University School of Nursing, Indianapolis, IN.
EMPEROR Reduced	
Presentation	Speaker(s)
Moderator (Introductions)	M. Packer; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX.
Primary Results with Emphasis on Major Primary and Secondary Endpoints and Safety	M. Packer; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX.
Comparison of Effects of Empagliflozin in Patients with HF With and Without Diabetes	S. Anker; Charité Medical School of the Humboldt University Berlin, Germany, Berlin, GERMANY.
Discussant	M. Costanzo; Advocate Heart Institute, Naperville, IL.
Comparison of DAPA-HF and EMPEROR-Reduced	F. Zannad; Hopital Brabois, CIC-P Inserm/CHU, Vandoeuvre-Les-Nancy, FRANCE.
Safety and Clinical Implications	G. Filippatos; University of Athens, Athens, GREECE.
Discussant	S. Greene; Duke University School of Medicine, Durham, NC.
Moderator (Panel / Q&A)	J. Pedro Ferreira; Centre Hospitalier Universitaire de Nancy, Laxou, FRANCE.
Case Study & Panel Discussion	
Management of HF in Rural/Frontier Areas: Challenges and Potential Solutions for Clinical Practice and Research	
Presentation	Speaker(s)
Moderator (Introductions)	J. Howie-Esquivel; University of Virginia School of Nursing.
Access to care in rural/frontier settings: Current challenges and potential solutions	W. Alonso; University of Nebraska College of Nursing.
GDMT Implementation in rural/frontier settings: Current challenges and potential solutions	R. Page; University of Colorado.
The importance of health literacy in rural/frontier settings	D. Moser; University of Kentucky College of Nursing.
Clinical Practice Challenges and Needs in Rural/Frontier Settings	L. L. Wick; University of MN, Duluth, MN.
Research Challenges and Needs in Rural/Frontier Settings	L. J. Graven; College of Nursing, Florida State University, Tallahassee, FL.
Moderator (Panel / Q&A)	D. Moser; University of Kentucky, Lexington, KY.
Case Study & Panel Discussion	
Myocarditis: Management Update	
Presentation	Speaker(s)
Moderator (Introductions)	J. Alexis; University of Rochester Medical Center, Rochester, NY.
2020 AHA Scientific Statement on the Management of Fulminant Myocarditis	J. C. Fang; University of Utah, Salt Lake City, UT.
Cardiac Sarcoidosis: A Not So Rare Cause of Cardiomyopathy	N. Gilotra; Johns Hopkins, Baltimore, MD.
Role of MRI and PET Imaging for the Diagnosis of Acute Myocardial Inflammation	R. Blankstein; Brigham and Women's Hospital, Boston, MA.
Choice of Mechanical Circulatory Support for Fulminant Myocarditis	H. Vidula; University of Rochester, Rochester, NY.
Ongoing Trials for Acute Myocarditis and Sarcoidosis	L. T. Cooper; Mayo Clinic, Jacksonville, FL.
Moderator (Panel /Q&A)	
Case Study & Panel Discussion	
Unfolding Development in the Care of Patients with TTR Cardiac Amyloidosis	
Presentation	Speaker(s)
Moderator (Introductions)	A. R. Patel; The CardioVascular Center, Tufts Medical Center, Boston, MA.
Understanding Cardiac Amyloidosis: Insights from the Bench	K. Alexander; Stanford University, Stanford, CA.
The Road to Diagnosis: Whom Do I Screen, When Do I Biopsy	B. Sperry; St. Lukes Mid America, Kansas City, MO.
Imaging for Cardiac Amyloidosis: Pearls and Pitfalls	S. Dorbala; Brigham and Womens, Boston, MA.
Advanced Heart Failure Therapies in the Patient with Cardiac Amyloid	J. Grodin; UT Southwestern, Dallas, TX.
Current and Emerging Therapies for Transthyretin Amyloidosis	M. Maurer; Columbia University, New York, NY.
Practical Tips for Pharmacotherapy Challenges in Transthyretin Amyloidosis, Including Helping Patients Navigate Access to Therapy	L. West; Cleveland Clinic, Cleveland, OH.
Moderator (Panel/ Q&A)	M. Hanna; Cardiology, Cleveland Clinic Foundation, Cleveland, OH.
Case Study & Panel Discussion	R. Witteles; Stanford University Medical Center, Stanford, CA.
Dangerous Liaisons in Pulmonary Hypertension	
Presentation	Speaker(s)
Moderator (Introductions)	M. A. Simon; University of Pittsburgh, Pittsburgh, PA.
Case 1: Double Trouble	P. Forfia; HFSA, Northfield, MN.
Case 2 - Double, Double, Toil and Trouble	S. Airhart; Providence Heart Institute, Portland, OR.
Case 3: How Unlucky Can You Get	A. Schnell Heringer; University of California - San Francisco, San Francisco, CA.
Panel Discussion and/or Q&A	
Panel Member 1	M. Gomberg-Maitland; George Washington University, Washington, DC.
Panel Member 2	H. Ventura; Ochsner Clinic Foundation, New Orleans, LA.
Panel Member 3	S. Murali; Allegheny Health Network, Pittsburgh, PA.
Panel Member 4	M. Kanwar; Allegheny General Hospital, Pittsburgh, PA.
Structural Interventions for A Falling Heart - A Partnership Between Interventional and HF Cardiologists	
Presentation	Speaker(s)
Moderator (Introductions)	J. Rosenthal; Mayo Clinic Arizona, Phoenix, AZ.
To Clip or Not to Clip: That Is the Debate! MitraClip Confirmed	J. Lindendorf; medicine, Vanderbilt University Medical Center, Nashville, TN.
To Clip or Not to Clip: that Is the Debate! MitraClip - Need More Data	M. Acker; University of Pennsylvania, Philadelphia, PA.
Percutaneous Tricuspid Valve Interventions: Myth or Reality	S. F. Bolling; Michigan Medicine University of Michigan, Ann Arbor, MI.

Transcatheter Aortic Valve Replacement for Patients with Low Ejection Fraction: Should It be Used for the Low Flow, Low Gradient State?	M. Reardon; Houston Methodist Hospital, Houston, TX.
Atrial unloading to treat ventricular dysfunction: conceptual framework and therapies	D. Burkhoff; Cardiovascular Research Foundation, New York, NY.
Moderator (Panel/ Q&A)	N. Uriel; Columbia Presbyterian University, New York, NY.
Case Study & Panel Discussion	
Advances in the Treatment of Monogenic Cardiomyopathies	
Presentation	Speaker(s)
Moderator (Introductions)	E. Adler; UCSD, La Jolla, CA.
Hypertrophic Cardiomyopathy - Out with the Old	J. Tardiff; University of Arizona, Tucson, AZ.
Dilated Cardiomyopathy - Personalizing Common Treatments	K. Sallam; Stanford University, Stanford, CA.
Risk Stratification and Management of Arrhythmogenic Cardiomyopathies	M. Maron; Tufts Medical Center, Boston, MA.
Practical Approaches to Patients Suspected of Genetic Cardiomyopathies	R. Hershberger; Ohio State University, Columbus, OH.
EXPLORER - HCM: What Have We Learned?	A. Masri; Oregon Health & Science University, Portland, OR.
Moderator (Panel / Q&A)	J. Wu; Stanford, CA.
Case Study & Panel Discussion	
Traversing Care and Guidelines for Patients with HF and Multiple Co-Morbidities	
Presentation	Speaker(s)
Moderator (Introductions)	S. Dunbar; Atlanta, GA.
Evaluation of the Patient with Heart Failure and Multiple Co-Morbidities: A Case Example	M. Walsh; St. Vincent Heart Center, Indianapolis, IN.
Patient Centered Care When Care is Complex: Setting Priorities with the Patient and Family	R. Gary; Emory University, Atlanta, GA.
Juggling and Sequencing Priorities in Patients with Multiple Co-morbidities	G. Levine; Baylor College of Medicine, Houston, TX.
When Do We Turn to Palliative Care Guidelines: Enabling the Patient and Family	A. S. Laramée; University of Vermont Medical Center, Burlington, VT.
Confronting Polypharmacy and Shared Decision-Making in Medication Management with Comorbidities and HF	T. Macaulay; University of Kentucky, Lexington, KY.
Moderator (Panel / Q&A)	B. Bozkurt; Baylor College of Medicine, Houston, TX.
Case Study & Panel Discussion	
Late Breaking Clinical Trials I (LBCT I)	
Presentation	Speaker(s)
Moderator (Introductions)	M. Mehra; Harvard University, Boston, MA.
Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In Ph-hfpef: Primary Results From The Help-ph-hfpef Multicenter Randomized Controlled Trial	Barry A. Borlaug ¹ , Daniel Burkhoff ² , Sanjiv Shah ³ , Ronald Zolty ⁴ , Ryan Tedford ⁵ , Thenappan Thenappan ⁶ , Roham Zamanian ⁷ , Jeremy Mazurek ⁸ , Jonathan Rich ³ , Marc Simon ⁹ , Stuart Rich ³ . ¹ Mayo Clinic, Rochester, MN; ² Columbia University, New York, NY; ³ Northwestern, Chicago, IL; ⁴ University of Nebraska, Omaha, NE; ⁵ Medical University of South Carolina, Charleston, SC; ⁶ University of Minnesota, Minneapolis, MN; ⁷ Stanford, Stanford Health Care, CA; ⁸ University of Pennsylvania, Philadelphia, PA; ⁹ UPMC Heart and Vascular Institute, Pittsburgh, PA
DISCUSSANT - Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In Ph-hfpef: Primary Results From The Help-ph-hfpef Multicenter Randomized Controlled Trial	K. Sharma; Medicine, Johns Hopkins Hospital, Baltimore, MD.
Mechanistic Insight Into The Effect Of Spironolactone For Preventing Heart Failure: Proteomics And Knowledge-based Network Analysis From The Homage Trial	Joao Pedro Ferreira. CIC-P Nancy, Vandoeuvre-les-Nancy, France
DISCUSSANT- Mechanistic Insight Into The Effect Of Spironolactone For Preventing Heart Failure: Proteomics And Knowledge-based Network Analysis From The Homage Trial	B. Pitt; cardiology, University of Michigan school of Medicine, Ann Arbor, MI.
Excess 30-Day Heart Failure Readmission In Blacks Increases With Neighborhood Deprivation	Shivani Anil Patel, Kaitlyn Long, Theresa E. Shirey, Neal J. Dickert, Alanna A. Morris. Emory University, Atlanta, GA
DISCUSSANT - Excess 30-Day Heart Failure Readmission In Blacks Increases With Neighborhood Deprivation	K. Ferdinand; Tulane University, New Orleans, LA.
Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)	J. J. McMurray; Institute of Cardiovascular and Medical Sciences-, Glasgow, BC.
DISCUSSANT - Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)	M. Weir; University of Maryland School of Medicine, Baltimore, MD.
Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Empirical Trials	Stefan D. Anker ¹ , Piotr Ponikowski ² , Christoph Wanner ³ , Egon Pfarr ⁴ , Sibylle Hauske ^{4,5} , Barbara Peil ⁴ , Afshin Salsali ⁶ , Ivana Ritter ⁴ , Matias Nordaby ⁴ , Audrey Koitka-Weber ^{3,4} , Martina Brueckmann ⁴ , Waheed Jamal ⁴ , JoAnn Lindenfeld ⁷ , William T. Abraham ^{1,8} . ¹ Charité University, Berlin, Germany; ² Wroclaw Medical University, Wroclaw, Poland; ³ Würzburg University Clinic, Würzburg, Germany; ⁴ Boehringer Ingelheim, Ingelheim, Germany; ⁵ University of Heidelberg, Heidelberg, Germany; ⁶ Boehringer Ingelheim, Ridgefield, CT; ⁷ Vanderbilt University Medical Center, Nashville, TN; ⁸ The Ohio State University, Columbus, OH
DISCUSSANT - Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Empirical Trials	S. S. Gottlieb; University of Maryland, Baltimore, MD.
Moderator (Panel / Q&A)	G. Filippatos; University of Athens, Athens, GREECE.
Case Study & Panel Discussion	
President Reception and Award Recognition	
Knowing It When You See It: Defining Congestion and Decongestion	
Presentation	Speaker(s)
Moderator (Introductions)	J. Thibodeau; UT Southwestern, Dallas, TX.
"Wet and Upset" - Why Congestion Is Such a Big Deal In Heart Failure	G. Felker; Duke Clinical Research Institute, Durham, NC.
True, True, and Related - Teasing out the Complex Interrelationship Between Volume Status and Congestion	W. L. Miller; Cardiovascular, Mayo Clinic, Rochester, MN.
The Ups and Downs of Natriuretic Peptides for Detecting Congestion	K. Adams, Jr.; University of North Carolina at Chapel Hill, Chapel Hill, NC.
Patients - You Can't Escape A Visit to the Doctor Just Yet	M. Drazner; UT Southwestern, Dallas, TX.
Trading In My Stethoscope for A Laptop - We Are Better Off Using Devices To Assess Congestion In Our Patients	A. B. Miller; Cardiology, University of Florida- Shands Jacksonville, Jacksonville, FL.
Moderator (LIVE Panel / Q&A)	A. M. Feldman; Temple University, Philadelphia, PA.
Case Study & Panel Discussion	
When Social Determinants Health Collide with HF Care and Treatment Decisions	
Presentation	Speaker(s)
Moderator (Introductions)	K. A. Sethares; Adult and Child Nursing, University of Massachusetts Dartmouth, North Dartmouth, MA.
Implicit and Explicit Bias In Medical Decision-Making	Q. Capers, IV; Ohio State University Medical Center, Columbus, OH.
Racial/Ethnic Disparities In Transplant and LVAD Candidacy	K. Breathett; University of Arizona, Tucson, AZ.
Gender Disparities In Transplant and LVAD Candidacy	A. A. Morris; Cardiology, Emory University, Atlanta, GA.
Psychosocial Economic Determinants of Advanced Heart failure and Treatment Outcomes: How to Appropriate address and Factor Into Candidacy	K. L. Grady; Northwestern Univeristy, Philadelphia, PA.
Advanced Heart Failure Selection Committees: How the Sausage is Made, and How We Can Make It Even Better	P. Khazanie; University of Colorado, Aurora, CO.
Moderator (Panel/Q&A)	L. L. Wick; University of MN, Duluth, MN.
Case Study & Panel Discussion	
New Data and Learnings from VICTORIA Trial	

Presentation	Speaker(s)
Moderator (Introductions)	P. Armstrong; Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, CANADA.
Defining an Optimal Standard of Background Medical Care : Insights from VICTORIA	J. Ezekowitz; AB, CANADA.
Recurrent Events After Hospitalization for Worsening Heart Failure: New findings from VICTORIA	R. J. Mentz; Duke University Medical Center, Durham, NC.
Discussant	W. C. Levy; Seattle, WA.
Prognostic Modelling in Patients with HFrEF and Recent Decompensation: Insights from VICTORIA	A. F. Hernandez; Durham, NC.
Where Does Vericiguat Fit in the Contemporary Standard of Care Management of HFrEF Care?	J. Butler; University of Mississippi, Jackson, MS.
Discussant	U. Elkayam; University of Southern California, Los Angeles, CA.
Panel Discussion / Q&A	
Moderator (Panel / Q&A)	C. O'Connor; Inova, Falls Church, VA.
International Session - Universal Definition of Heart Failure	
Presentation	Speaker(s)
Introduction to Mihai Gheorghide Lectureship	B. Bozkurt; Baylor College of Medicine, Houston, TX.
Mihai Gheorghide Lectureship: The Five Alive	J. J. McMurray; University of Glasgow, Glasgow, UNITED KINGDOM.
Introduction to International Session	B. Bozkurt; Baylor College of Medicine, Houston, TX.
Proposed Universal Definition of HF	A. J. Coats; University of Monash, Coventry, UNITED KINGDOM.
Proposed Classifications of HF According to EF	K. Yamamoto; Tottori University, Yonago, JAPAN.
Proposed Stages of HF	B. Bozkurt; Baylor College of Medicine, Houston, TX.
Definitions According to Clinical and EF Trajectory	S. Zieroth; University of Manitoba, Winnipeg, MB, CANADA.
Awarding of Honorary International FHFS Andrew Coats, MD of the United Kingdom/Maria Crespo-Liero, MD of Spain Tiny Jaarsma, RN of Sweden John McMurray, MD of Scotland	B. Bozkurt; Houston, TX.
Cardiogenic Shock in 2020: Evolving Definitions, Devices and Delivery	
Presentation	Speaker(s)
Moderator (Introductions)	S. Hall; Baylor University Medical Center.
Challenges in Defining and Classifying Cardiogenic Shock: Why It is Important to Speak a Unified Language	D. Baran; Sentare Healthcare.
Coming Together: How to Build A Multidisciplinary Shock Team	M. Givertz; Brigham and Women's Hospital, Boston, MA.
The Toolbox of the Shock Team in 2020: Hemodynamic Effects of Acute MCS Devices	N. Uriel; Columbia University Medical Center.
How to Approach Percutaneous MCS for Shock Patients On the Transplant List	U. Jorde; Bronx, NY.
The Modern CICU: A Multidisciplinary Comprehensive Critical Care Unit for the Entire Arc of Heart Failure, Transplant, and MCS	D. Berg; Brigham and Women's Hospital, Boston, MA.
A Challenging Case in Cardiogenic Shock: Focus on Acute MI	E. E. Vorovich; Chicago, IL.
Challenging Cases in Cardiogenic Shock: Focus on Acute on Chronic Heart Failure	A. Garan; Beth Israel Deaconess Medical Center.
Moderator (Panel / Q&A)	J. Fried; Columbia University Medical Center.
Panel Discussion / Q&A	
DAPA-HF: One Year On	
Presentation	Speaker(s)
Moderator (Introductions)	J. N. Cohn; University of Minnesota, Minneapolis, MN.
DAPA-HF: Additional and Exploratory Clinical Outcomes	M. Kosiborod; Saint Luke's Cardiovascular Consultants, Kansas City, MO.
DAPA-HF: Renal Outcomes	S. Solomon; Brigham and Women's Hospital, Boston, MA.
Discussant	I. Pina; Detroit, MI.
DAPA-HF:Diuretic Therapy	J. J. McMurray; Cardiovascular Research Centre, Glasgow-, UNITED KINGDOM.
DAPA-HF: Other Background Therapy Subgroups	L. Kober; Rigshospitalet University of Copenhagen, Copenhagen, DENMARK.
Discussant	J. G. Cleland; Glasgow, UNITED KINGDOM.
Moderator (Panel / Q&A)	K. Adams, Jr.; University of North Carolina at Chapel Hill, Chapel Hill, NC.
Panel Discussion / Q&A	
Women in HF Career Forum	
Presentation	Speaker(s)
Moderator (Introductions)	B. Bozkurt; Baylor College of Medicine, Houston, TX.
HFSA & Women in Heart Failure	J. Lindenfeld; Vanderbilt University Medical Center, Nashville, TN.
Keys to Success: Grit, Grace and Definitions	L. Stevenson; Vanderbilt Heart & Lung Institute, Nashville, TN.
Imposter Syndrome: Recognize and Overcome It	M. Ginwalla; Cardiology, Palo Alto Medical Foundation/Sutterhealth, Palo Alto, CA.
Research, Scholarship and the Power of the Pen	R. M. Masterson Creber; Healthcare Policy & Research, Weill Cornell Medicine, New York City, NY.
Dr. Mom's Balancing Act to Juggle the Puzzle & Thrive	I. Pina; Wayne State University, Detroit, MI.
Taking Mentorship One-Step Further	J. E. Rodgers; UNC Eshelman School of Pharmacy, Chapel Hill, NC.
Moderator (Panel / Q&A)	S. Ammon; San Francisco, CA.
Panel Discussion / Q&A	
Cardiac Cachexia: Mechanisms, Measuring Muscle, and Managing Malnutrition	
Presentation	Speaker(s)
Moderator (Introductions)	L. M. Freeman; Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA.
Moderator (Panel / Q&A)	S. von Haehling; Charite Campus Virchow-Klinikum, Berlin, GERMANY.
Why Should We Take Notice of Skeletal Muscle Wasting in Patients with Heart Failure	A. Coats; Monash University, Melbourne, AUSTRALIA.
Defining Cardiac Cachexia: How Do We Develop Therapies for A Condition Without Diagnostic Criteria	S. Anker; Charite Campus Virchow-Klinikum, Berlin, GERMANY.
Molecular Mechanisms and Promising Pharmacological Therapies for Patients with Cardiac Cachexia	A. Vest; Tufts Medical Center, Boston, MA.
Overlap of Cardiac Cachexia and Cancer Cachexia	M. S. Anker; Charité – Universitätsmedizin Berlin, Berlin, GERMANY.
Does Malnutrition Drive Cardiac Cachexia?	L. Parsly; Frances Stern Nutrition Center, Tufts Medical Center, Boston, MA.
Panel Discussion / Q&A	
Targeting Therapy for HFpEF	
Presentation	Speaker(s)
Moderator (Introductions)	A. Kalogeropoulos; Medicine (Cardiology), Stony Brook University, Stony Brook, NY.
Scores and More: Diagnostic Approaches for HFpEF	A. S. Desai; Heart and Vascular Center, Brigham and Women's Hospital, Boston, MA.
Back to the Basics: Can Animal Models of HFpEF Better Guide Therapeutic Strategies?	J. Hill; Ut Southwestern, Dallas, TX.
Machine Learning to Guide Therapeutic Strategic in HFpEF: Fact or Fiction?	T. Ahmad; Yale School of Medicine, New Haven, CT.
What Have We Learned from Clinical Trials of Medical Therapy in HFpEF: The Path Forward	S. Shah; Northwestern University, Feinberg School of Medicine, Chicago, IL.
Interventional Strategies to Treat HFpEF: Are They Going to Solve the Problem?	M. Fudim; Duke University, Durham, NC.
Moderator (Panel / Q&A)	P. E. Carson; Washington VAMC, Washington DC, DC.
Panel Discussion / Q&A	
Remote Monitoring for HF - Specialized Devices and ICDs	
Presentation	Speaker(s)
Introduction- COVID-19 Implications for Heart Failure Population	K. Breathett; University of Arizona, Tucson, AZ.
Innovation With Remote Heart Failure Monitoring Of The Past, Present, And Future	W. T. Abraham; Division of Cardiovascular Medicine, Ohio State University, Columbus, OH.
Case 1 - Remote Monitoring During COVID-19 - Ambulatory Pulmonary Artery Pressure Monitoring	S. Mazimba; University of Virginia, Charlottesville, VA.

Case 1 - Remote Monitoring During COVID-19 - Ambulatory Pulmonary Artery Pressure Monitoring	C. T. Williams; Henry Ford Hospital, Detroit, MI.
Case 2 - Remote Monitoring During COVID-19 - Electronic remote monitoring interfaces for VAD	A. J. Hicks, III; Baylor Scott & White, Round Rock, TX.
Case 2 - Remote Monitoring During COVID-19 - Electronic remote monitoring interfaces for VAD	L. Klein; UCSF, San Francisco, CA.
Case 3 - Remote Monitoring During COVID-19 - Intrathoracic impedance monitoring	K. Flint; University of Colorado, Denver, CO.
Case 3 - Remote Monitoring During COVID-19 - Intrathoracic impedance monitoring	S. Hall; Baylor Scott & White Advanced Heart Failure Clinic, Dallas, TX.
Case 4 - Remote Monitoring During COVID-19 -Remote cardiac examination	S. Zalawadiya; Vanderbilt University, Nashville, TN.
Case 4 - Remote Monitoring During COVID-19 -Remote cardiac examination	A. J. Sauer; University of Kansas, Fairway, KS.
Case 4 - Remote Monitoring During COVID-19 -Remote cardiac examination	D. Lanfear; Henry Ford Hospital, Detroit, MI.
Discussant - Wrap Up	K. Breathett; University of Arizona, Tucson, AZ.
Panelist	M. Psotka; Inova Heart and Vascular Institute, Falls Church, VA.
Panelist	T. Alexy; Emory University, Atlanta, GA.
Panelist	M. Ginwalla; Sutterhealth/Palo Alto Medical Foundation, Palo Alto, CA.
Panelist (Medtronic)	S. Sarkar; Medtronic, Minneapolis, MN.
Panelist (Ekos)	L. Le; Ekos, Charlotte, NC.
Women and Gender Influences in Heart Failure	
Presentation	Speaker(s)
Moderator (Introductions)	M. Mogos; Vanderbilt University School of Nursing, Nashville, TN.
Women and Gender Influences in Heart Failure	J. E. Ho; Massachusetts General Hospital, Boston, MA.
Sex Differences in Chemotherapy-Induced Cardiomyopathy	M. Bloom; Stony Brook University, New York, NY.
Are There Sex Differences in Heart Failure Treatments: Medications, Mechanical Circulatory Support and Transplantation	E. M. DeFilippis; Columbia University Irving Medical Center, New York, NY.
Heart Failure Treatment in Women: Exercise and Cognitive Behavior Therapy - What Works?	R. Gary; Emory University, Atlanta, GA.
Heart Failure Across the Pregnancy Continuum: A Rising Concern	J. Briller; University of Illinois, Chicago, IL.
Moderator (Panel / Q&A)	S. Mohammed; Medstar Heart and Vascular Institute, Washington, DC.
Panel Discussion / Q&A	
Understanding Heart Failure with Recovered Ejection Fraction	
Presentation	Speaker(s)
Moderator (Introductions)	E. Shao; Tufts University, Maine Medical Center, South Portland, ME.
Recovering Cardiac Function After Injury: Lessons from the Laboratory	W. Koch; Temple University, Philadelphia, PA.
Resynchronization Super-Responders: Who, Why and What Next?	R. Kahwash; Columbus, OH.
Prioritizing Polypharmacy in Recovered Ejection Fraction	J. Wilcox; Medicine-Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Recovering Ejection Fraction After Viral Myocarditis, Who, Why, and What Are We Going Learning from COVID-19?	S. Pinney; University of Chicago, Chicago, IL.
Moderator (Panel/Q&A)	K. B. Margulies; University of Pennsylvania School of Medicine, Philadelphia, PA.
Panel Discussion/Q&A	
Integrated Omics in Heart Failure: Precision Medicine Highlights for HF Clinicians and Scientists	
Presentation	Speaker(s)
Moderator (Introductions)	M. Piano; Vanderbilt University, Nashville, TN.
To Screen or Not to Screen: Approach to Clinical Genetic Testing in Patients with Heart Failure	A. Owens; University of Pennsylvania, Philadelphia, PA.
Proteomics: From Discovery to Validated Biomarkers	M. Naylor; Massachusetts General Hospital, Boston, MA.
Understanding the Role of the Gut Microbiome in Heart Failure	W. Tang; Cleveland Clinic, Cleveland, OH.
Pharmacogenomics: Are We Ready for Prime Time?	D. Lanfear; Henry Ford Hospital, Detroit, MI.
The Case for Diversity to Enhance the Impact of Precision Medicine Research	L. Hindorff; National Human Genome Research Institute, Bethesda, MD.
Moderator (Panel / Q&A)	J. Luzum; University of Michigan, Ann Arbor, MI.
Panel Discussion/Q&A	
The Intersection of Cardio-Oncology and Advanced Heart Failure: From Stage A to D	
Presentation	Speaker(s)
Moderator (Introductions)	D. Lenihan; Washington School of Medicine at St. Louis, St. Louis, MO.
Building a Successful Cardio-Oncology Program 101	J. Durand; MD Anderson Cancer Center, Houston, TX.
Screening for Cardiotoxicity: Imaging? Biomarkers? or None at All	J. Liu; Memorial Sloan Kettering Cancer Center, Manhattan, NY.
What's Old, New and Emerging About Cardiotoxicity?	A. Barac; Medstar Washington Hospital Center, Washington DC, DC.
Immunotherapy and Cardiac Dysfunction: From Mechanisms to Therapy	J. Moslehi; Vanderbilt University Medical Center, Nashville, MS.
Advanced Cardio-oncology: What About LVAD and Heart Transplant Patients?	J. Raikhelkar; Columbia University Medical Center, New York, NY.
Moderator (Panel Q&A)	A. Nohria; Brigham and Women's Hospital, Boston, MA.
Panel Discussion/Q&A	
Atrial Fibrillation and Heart Failure: The Beat Goes On	
Presentation	Speaker(s)
Moderator (Introductions)	S. Zieroth; University of Manitoba, Winnipeg, MB, CANADA.
Cardiomyopathy or Atrial Myopathy: Understanding Pathophysiology	A. Ducharme; Medicine, Montreal Heart Institute, Montreal, QC, CANADA.
Comparing and Contrasting the US and Canadian Guidelines (Rate/Rhythm/Ablation)	J. Andrade; Vancouver Coastal Health, Vancouver, BC, CANADA.
HFpEF and Atrial Fibrillation as a Phenotype	K. Sharma; Medicine, Johns Hopkins Hospital, Baltimore, MD.
Moderator (Panel with Q&A)	
Panelist	C. Albert; Cedars Sinai, Los Angeles, CA.
Panel Discussion	
Implementation: Systematic Strategies of Improving Care and Outcomes	
Presentation	Speaker(s)
Moderator (Introductions)	N. M. Albert; Nursing Institute-Research and Innovation, Cleveland Clinic, Cleveland, OH.
Overcoming Clinical Inertia in Use and Dosing of GDMT	S. Greene; Duke University School of Medicine, Durham, NC.
How to Get SGLT2 Inhibitors and Other New Therapies Into Clinical Use	O. Vardeny; Minneapolis VA Health Care System, Minneapolis, MN.
Implementing Patient Reported Outcome Measures in Clinical Practice	J. Spertus; University of Missouri - Kansas City, Kansas City, MO.
Health Care Policies that Could Incentivize Implementation in HF	K. Joyn't Maddox; Washington University, St. Louis, MO.
Moderator (Panel / Q&A)	G. Fonarow; University of California, Los Angeles, CA.
Panel Discussion / Q&A	
Clinical-Pathological Cases (CPC): Stump the Professor	
Presentation	Speaker(s)
Moderator	M. Drazner; UT Southwestern, Dallas, TX.
Case 1	A. Lala; Mount Sinai, New York, NY.
Case 2	M. Nassif; Saint Lukes Mid America Heart Institute, Kansas City, MO.
PROFESSOR Panelist	B. Greenberg; University California San Diego, La Jolla, CA.
PROFESSOR Panelist	M. Konstam; Tufts Medical Center, Boston, MA.
PROFESSOR Panelist	M. Mehra; Brigham and Women's Hospital / Harvard University, Boston, MA.

Patient Pearls for Advanced Heart Failure: A View from the Other Side	
Presentation	Speaker(s)
Moderator (Introductions)	S. E. Schroeder; Bryan Heart, Lincoln, NE.
What is High Value Care?	L. Allen; University of Colorado School of Medicine, Denver, CO.
Tomorrow Belongs to Those Who Prepare for It Today: Leaning Into Advanced Heart Failure	A. Anderson; UT Health San Antonio, San Antonio, TX.
You Want to Do What to Me? Preparing for Cardiac Procedures	M. Bloom; Stony Brooke University, New York, NY.
It Is A Team Sport: The Joys and Challenges of Family Caregiving	T. Jaarsma; Linkoping University, Linkoping, SWEDEN.
Patient Panelist	C. Chauhan; Patient Advocate, Wichita, KS.
Patient Panelist	R. Monroe; None, Washington, DC.
Moderator (Panel/Q&A)	S. Gale; University of Maryland School of Pharmacy, Baltimore, MD.
Panel Discussion / Q&A (with Patients and Session Faculty)	
Late Breaking Clinical Trials II (LBCT II)	
Presentation	Speaker(s)
Moderator (Introductions)	P. Liu; University of Ottawa Heart Institute, Ottawa, ON, CANADA.
Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial	Michael E. Nassif1, Mohammed Qintar1, Sheryl L. Windsor1, Rita Jermyn2, David M. Shavelle3, Fengming Tang1, Sumant Lamba4, Kunjan Bhatt5, John Brush6, Andrew B. Civitello7, Robert A. Gordon8, Orvar Jonsson9, Brent C. Lampert10, Jamie Pelzel11, Mikhail Kosibrod1, 1Saint Luke's Mid America Heart Institute, Kansas City, MO; 2St. Francis Hospital, New York, NY; 3University of Southern California, Los Angeles, CA; 4First Coast Cardiovascular Institute, Jacksonville, FL; 5Austin Heart, Austin, TX; 6Sentara Healthcare, Norfolk, VA; 7Baylor College of Medicine, Houston, TX; 8NorthShore University HealthSystem, Evanston, IL; 9University of South Dakota Sanford Health, Sioux Falls, SD; 10Ohio State University, Columbus, OH; 11CentraCare Heart and Vascular Center, St. Cloud, MN
Discussant - Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial	L. Stevenson; Vanderbilt University, Nashville, TN.
Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy	Justin Ezekowitz1, Ciaran McMullan2, Cynthia Westerhout1, Ileana L. Pina3, Jose Lopez-Sendon4, Kevin J. Anstrom5, Adrian F. Hernandez5, Carolyn S. P. Lam6, Christopher M. O'Connor7, Burkert Pieske8, Piotr Ponikowski9, Lothar Roessig10, Adriaan A. Voors11, Joerg Koglin2, Paul W. Armstrong1, Javed Butler12, 1CVC, U Alberta, Edmonton, AB, Canada; 2Merck, Kenilworth, NJ; 3Wayne State U, Detroit, MI; 4U Hosp La Paz, Madrid, Spain; 5DCRI, Durham, NC; 6Nat Heart Ctr, Singapore, Singapore; 7Inova, Falls Church, VA; 8Charité U Med, Berlin, Germany; 9Wroclaw Med U, Wroclaw, Poland; 10Bayer, Wuppertal, Germany; 11U Groningen, Groningen, Netherlands; 12U Mississippi, Jackson, MS
DISCUSSANT - Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy	J. Januzzi; Massachusetts General Hospital, Boston, MA.
A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction	Kieran F. Docherty1, Ross T. Campbell1,2, Katriona J. M. Brooksbank1, Rosemary L. Godeseth1, Paul Forsyth3, Alex McConnachie4, Giles Roditi1,5, Bethany Stanley4, Paul Welsh1, Pardeep S. Jhund1, Mark C. Petrie1, John J. V. McMurray1. 1Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom; 2Queen Elizabeth University Hospital, Glasgow, United Kingdom; 3Pharmacy Services, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom; 4Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom; 5Glasgow Royal Infirmary, Glasgow, United Kingdom
DISCUSSANT - A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction	J. Udelson; Tufts Medical Center, Boston, MA.
Endovascular Ablation Of The Right Greater Splanchnic Nerve For The Treatment Of Heart Failure With Preserved Ejection Fraction - First-in-human Clinical Trial	Sanjiv J. Shah1, Teona Zirakashvili2, Nikoloz Shaburishvili2, Giorgi Shaishmelashvili2, Horst Sievert3, Kolja Sievert3, Anisha Bapna4, Zoar J. Engelman4, Daniel Burkhoff5, Tamaz Shaburishvili2. 1Northwestern University Feinberg School of Medicine, Chicago, IL; 2Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia; 3Cardiovascular Center Frankfurt, Sankt Katharinen, Frankfurt, Germany; 4Axon Therapies, New York City, NY; 5Cardiovascular Research Foundation, New York City, NY
DISCUSSANT - Endovascular Ablation Of The Right Greater Splanchnic Nerve For The Treatment Of Heart Failure With Preserved Ejection Fraction - First-in-human Clinical Trial	M. Redfield; Mayo Foundation, Rochester, MN.
Effect Of Empagliflozin On Major Heart Failure Outcomes, Renal Function And Quality Of Life In Patients With Heart Failure With A Reduced Ejection Fraction, With And Without Sacubitril/Valsartan	Milton Packer1,2. 1Baylor University Medical Center, Dallas, TX; 2Imperial College, London, United Kingdom
DISCUSSANT - Effect Of Empagliflozin On Major Heart Failure Outcomes, Renal Function And Quality Of Life In Patients With Heart Failure With A Reduced Ejection Fraction, With And Without Sacubitril/Valsartan	B. L. Claggett; Brigham and Women's Hospital, Boston, MA.
Moderator (Panel / Q&A)	G. Felker; Duke Clinical Research Institute, Durham, NC.
Panel Discussion / Q&A	
Navigating the Early Career Waters: Pearls for Achieving Success - What They Didn't Teach You in Training	
Presentation	Speaker(s)
Moderator (Introductions)	B. Van Tassel; Virginia Commonwealth University, Richmond, VA.
Early Career Challenges in a Research-Intensive Position	Q. E. Denfeld; Oregon Health & Science University, Portland, OR.
Early Career Challenges in a Clinically-Focused Position at an Academic Medical Center	A. Bhimaraj; Houston Methodist hospital, Houston, TX.
Early Career Challenges in a Position Outside Academia (Research and Clinical)	P. A. Patel; Atrium Health, Concord, NC.
Work-Life Challenges	L. Rose-Jones; University of North Carolina, Chapel Hill, NC.
Lessons Learned	S. Wingate; National Institute of Nursing Research, Bethesda, MD.
Lessons Learned	T. Lennie; University of Kentucky College of Nursing, Lexington, KY.
Moderator (Panel Q&A)	S. Greene; Duke University School of Medicine, Durham, NC.
Case Study & Panel Discussion	
Paper of the Year from Top HF Journals	
Presentation	Speaker(s)
Moderator (Introductions)	M. Rich; Washington University, St. Louis, MO.
Paper of the Year - Journal of Cardiac Failure (JCF)	M. Rich; St. Louis, MO.
Paper of the Year - JACC-HF	C. O'Connor; Inova, Falls Church, VA.
Best Paper of the Year - Journal of Heart and Lung Transplant (JHLT)	M. Mehra; Brigham and Women's Hospital / Harvard Medical School, Boston, MA.
Paper of the Year - Circulation: HF (Circ-HF)	N. Sweitzer; Arizona EDU, Arizona, AZ.
Paper of the Year - European Journal of HF (EJHF)	M. Metra; University of Brescia, Brescia, ITALY.
Moderator (Live Panel Q&A)	T. M. Ng; School of Pharmacy, University of Southern California, Los Angeles, CA.
Panel Discussion with Q&A	
Management of the Medically Complex Patient	
Presentation	Speaker(s)
Welcomes and Introductions	
Case 1 - Diuretic Resistance - Choose Your Own Adventure Format	B. Moyer; Duke, Durham, NC.
Case 2 - Peripartum Cardiomyopathy - Choose Your Own Adventure Format	K. Faulkenberg; Cleveland Clinic, Cleveland, OH.
Case 3 - Optimization of Heart Failure Therapies in Patients Hospitalized for Non-Cardiovascular Conditions - Choose your Own Adventure Format	L. Buckley; Brigham and Women's Hospital/Harvard Medical School, Boston, MA.
Speaker / Panelist	A. S. Laramée; University of Vermont Medical Center, Burlington, VT.

Speaker / Panelist	J. E. Rodgers; UNC Eshelman School of Pharmacy, Chapel Hill, NC.
Speaker / Panelist	C. Chauhan; Patient Advocate, Wichita, KS.
Speaker / Panelist	N. Ibrahim; Cardiology, Massachusetts General Hospital, Boston, MA.
Speaker / Panelist	M. Psotka; Inova Heart and Vascular Institute, Falls Church, VA.
Closing Remarks	
The Economics of Heart Failure -- Exploring Social Determinants and Financial Burden in the Care of Patients with HF	
Presentation	Speaker(s)
Moderator (Introductions)	K. D. DiPalo; Montefiore Medical Center, Bronx, NY.
Financial Toxicity - What Is It and What Are the Implications?	K. Nasir; Houston Methodist, Houston, TX.
Assessment of Financial Burden and Its Impact on Health Outcomes	S. D. Slavin; Medicine, Brigham and Women's Hospital, Boston, MA.
Intersection of Financial Burden with Health Disparities	C. W. Yancy; Northwestern University, Chicago, IL.
The Economics of Advanced Therapies	L. Davis; University of North Carolina, Chapel Hill, NC.
Interventions and Policy Innovation to Address Social Determinants of Health and Financial Burden	P. Heidenreich; Stanford VA Palo Alto Medical Center, Palo Alto, CA.
Moderator (Panel / Q&A)	N. Sweitzer; University of Arizona, Tucson, AZ.
Panel Discussion / Q&A	
Dr. Alexa is In: Leveraging Technology in Heart Failure Care	
Presentation	Speaker(s)
Moderator (Introductions)	K. A. Sethares; Adult and Child Nursing, University of Massachusetts Dartmouth, North Dartmouth, MA.
The Future of Wearables in Patients with Heart Failure	A. D. DeVore; Duke University Medical Center, Durham, NC.
Always Watching: Remote Monitoring	M. Fraser; University of Minnesota, Minneapolis, MN.
Are Virtual Visits the New Reality?	E. Gorodeski; Case Western Reserve University, Cleveland, OH.
Beyond the After-Visit Summary to Educate and Engage Patients	E. Kellison; CHI Franciscan Health, Tacoma, WA.
Information Dissemination in the Era of Facebook and Twitter	M. Kittleson; Cedars-Sinai California Heart Center, Beverly Hills, CA.
Moderator (Panel / Q&A)	C. McIlvennan; University of Colorado, Boulder, CO.
Panel Discussion / Q&A	Faculty
TEACH Workshop	
Presentation	Speaker(s)
Moderator	D. Burkhoff; West Harrison, NY.
Research Network Update	
Presentation	Speaker(s)
Moderator (Introductions)	M. Fluzat; Duke, Durham, NC.
HF Collaboratory / HFSA Joint Site Base Research Awards	C. O'Connor; Inova, Falls Church, VA.
Trial Conduct in the Era of COVID-19 and Beyond - Industry Trial	F. I. Malik; Cytokinetics, San Francisco, CA.
Trial Conduct in the Era of COVID-19 and Beyond - NIH Trial (LOFT)	W. T. Abraham; The Ohio State University Wexner Medical Center, Columbus, OH.
Best Practices During COVID-19: Remote Monitoring and End Points	C. O'Connor; Inova, Falls Church, VA.
Case Study & Panel Discussion	